Sun Primes Late-Stage Psoriasis Asset With Samsung Manufacturing Deal

Sun Pharma has firmed up a manufacturing pact for tildrakizumab with Samsung BioLogics, securing supplies of its late-stage psoriasis asset in an increasingly competitive segment. The deal also underscores Samsung’s expanding stature as a frontline CMO in the biologics space.